Grossi F, et al. - In the present study, researchers tested the effectiveness and safety of nivolumab (an immune checkpoint inhibitor) in elderly patients with stage IIIB or IV squamous non–small-cell lung cancer (NSCLC) recruited in the expanded access program (EAP) in Italy. Between April 2015 and September 2015, 371 subjects with squamous NSCLC were recruited at 96 centers. Findings revealed that these patients benefited from nivolumab. They found that the median overall survival was decreased for ages ≥ 75 years (5.8 months) vs all other ages (8.0 months). The present data indicated that safety and tolerability with nivolumab were comparable, irrespective of age.